Microparticles as new markers of cardiovascular risk in diabetes and beyond

• Published in: Thrombosis and haemostasis Vol. 116; no. 2; p. 220
• Main Authors: Santilli, Francesca, Marchisio, Marco, Lanuti, Paola, Boccatonda, Andrea, Miscia, Sebastiano, Davì, Giovanni
• Format: Journal Article
• Language: English
• Published: Germany 01.08.2016
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - etiology; Atherosclerosis - blood; Atherosclerosis - etiology; Biomarkers - blood; Blood Platelets - pathology; Cardiovascular Diseases - blood; Cardiovascular Diseases - etiology; Cell-Derived Microparticles - pathology; Diabetes Mellitus - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetic Cardiomyopathies - blood; Diabetic Cardiomyopathies - etiology; Endothelial Cells - pathology; Humans; Plaque, Atherosclerotic - blood; Plaque, Atherosclerotic - etiology; Risk Factors; Stroke - blood; Stroke - etiology; Thromboplastin - metabolism; atherosclerosis; platelet; tissue factor; diabetes; Microparticles
• DOI: 10.1160/TH16-03-0176

The term microparticle (MP) identifies a heterogeneous population of vesicles playing a relevant role in the pathogenesis of vascular diseases, cancer and metabolic diseases such as diabetes mellitus. MPs are released by virtually all cell types by shedding during cell growth, proliferation, activation, apoptosis or senescence processes. MPs, in particular platelet- and endothelial-derived MPs (PMPs and EMPs), are increased in a wide range of thrombotic disorders, with an interesting relationship between their levels and disease pathophysiology, activity or progression. EMP plasma levels have been associated with several cardiovascular diseases and risk factors. PMPs are also shown to be involved in the progressive formation of atherosclerotic plaque and development of arterial thrombosis, especially in diabetic patients. Indeed, diabetes is characterised by an increased procoagulant state and by a hyperreactive platelet phenotype, with enhanced adhesion, aggregation, and activation. Elevated MP levels, such as TF+ MPs, have been shown to be one of the procoagulant determinants in patients with type 2 diabetes mellitus. Atherosclerotic plaque constitutes an opulent source of sequestered MPs, called "plaque" MPs. Otherwise, circulating MPs represent a TF reservoir, named "blood-borne" TF, challenging the dogma that TF is a constitutive protein expressed in minute amounts. "Blood-borne" TF is mainly harboured by PMPs, and it can be trapped within the developing thrombus. MP detection and enumeration by polychromatic flow cytometry (PFC) have opened interesting perspectives in clinical settings, particularly for the evaluation of MP numbers and phenotypes as independent marker of cardiovascular risk, disease and outcome in diabetic patients.